Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.81 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.81 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.57 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.57 |
| ▸ | GRK5 | P34947 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565212 | 0.93 | S1PR5 (0.87) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL30500506 | 0.90 | S1PR5 (0.72) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL1438433 | 0.90 | S1PR5 (0.72) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL3027737 | 0.90 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL5636102 | 0.89 | S1PR5 (0.67) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL1439660 | 0.89 | S1PR5 (0.70) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL2330642 | 0.87 | S1PR5 (0.68) | S1PR5S1PR1FUCA1 | |
| SCHEMBL5639896 | 0.86 | S1PR5 (0.76) | S1PR5S1PR1 | |
| SCHEMBL6745182 | 0.85 | S1PR5 (0.65) | S1PR5S1PR1FUCA1 | |
| SCHEMBL3042076 | 0.83 | S1PR1 (0.77) | S1PR5S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | S1PR5 4454/4885S1PR1 4182/4885S1PR3 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.